More than 800 people are participating in a Phase II clinical trial of a Lyme disease vaccine that could be on the market within five years, says Thomas Lingelbach, CEO of developer Valneva. The company is also working on a vaccine for mosquito-borne Chikungunya virus.
Sign up for Animal Health SmartBrief
News for animal health professionals
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.